Active Biotech AB (ACTI) - Total Liabilities
Based on the latest financial reports, Active Biotech AB (ACTI) has total liabilities worth Skr11.00 Million SEK (≈ $1.18 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ACTI financial resilience to evaluate the company's liquid asset resilience ratio.
Active Biotech AB - Total Liabilities Trend (2000–2025)
This chart illustrates how Active Biotech AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Active Biotech AB balance sheet assets.
Active Biotech AB Competitors by Total Liabilities
The table below lists competitors of Active Biotech AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gratifii Ltd
AU:GTI
|
Australia | AU$16.47 Million |
|
Cannabist Company Holdings Inc
NEO:CBST
|
Canada | CA$689.46 Million |
|
Vaishali Pharma Limited
NSE:VAISHALI
|
India | Rs-691.15 Million |
|
ICH Co Ltd
KQ:368600
|
Korea | ₩70.61 Billion |
|
Putprop Ltd
JSE:PPR
|
South Africa | ZAC477.30 Million |
|
Sri Adhikari Brothers Television Network Limited
NSE:SABTNL
|
India | Rs171.45 Million |
|
Kintavar Exploration Inc
V:KTR
|
Canada | CA$961.44K |
|
VR Resources Ltd
V:VRR
|
Canada | CA$233.89K |
Liability Composition Analysis (2000–2025)
This chart breaks down Active Biotech AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ACTI equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Active Biotech AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Active Biotech AB (2000–2025)
The table below shows the annual total liabilities of Active Biotech AB from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr14.60 Million ≈ $1.57 Million |
+31.18% |
| 2024-12-31 | Skr11.13 Million ≈ $1.20 Million |
-16.82% |
| 2023-12-31 | Skr13.38 Million ≈ $1.44 Million |
-18.88% |
| 2022-12-31 | Skr16.49 Million ≈ $1.78 Million |
+62.82% |
| 2021-12-31 | Skr10.13 Million ≈ $1.09 Million |
+0.88% |
| 2020-12-31 | Skr10.04 Million ≈ $1.08 Million |
-23.76% |
| 2019-12-31 | Skr13.17 Million ≈ $1.42 Million |
-93.86% |
| 2018-12-31 | Skr214.52 Million ≈ $23.09 Million |
-5.14% |
| 2017-12-31 | Skr226.14 Million ≈ $24.34 Million |
-1.82% |
| 2016-12-31 | Skr230.32 Million ≈ $24.79 Million |
-14.33% |
| 2015-12-31 | Skr268.84 Million ≈ $28.93 Million |
-15.25% |
| 2014-12-31 | Skr317.21 Million ≈ $34.14 Million |
-12.47% |
| 2013-12-31 | Skr362.40 Million ≈ $39.00 Million |
+1.56% |
| 2012-12-31 | Skr356.82 Million ≈ $38.40 Million |
+0.08% |
| 2011-12-31 | Skr356.53 Million ≈ $38.37 Million |
+10.95% |
| 2010-12-31 | Skr321.34 Million ≈ $34.58 Million |
+3.70% |
| 2009-12-31 | Skr309.86 Million ≈ $33.35 Million |
+0.17% |
| 2008-12-31 | Skr309.34 Million ≈ $33.29 Million |
+3.12% |
| 2007-12-31 | Skr299.97 Million ≈ $32.28 Million |
-25.39% |
| 2006-12-31 | Skr402.04 Million ≈ $43.27 Million |
+2.81% |
| 2005-12-31 | Skr391.05 Million ≈ $42.08 Million |
+159.68% |
| 2004-12-31 | Skr150.59 Million ≈ $16.21 Million |
+169.76% |
| 2003-12-31 | Skr55.82 Million ≈ $6.01 Million |
-36.01% |
| 2002-12-31 | Skr87.24 Million ≈ $9.39 Million |
+26.51% |
| 2001-12-31 | Skr68.96 Million ≈ $7.42 Million |
-69.07% |
| 2000-12-31 | Skr222.92 Million ≈ $23.99 Million |
-- |
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye disea… Read more